Group items tagged

The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation. It doesn't stop there, but HIPAA penalties won't apply to covered healthcare providers for practicing telehealth medicine using third-party applications such as Skype or Facebook Messenger

The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation.

Single-use medical device reprocessing refers to cleaning, disinfection, testing, sterilization, and remanufacturing of a used medical device to be put in service again. The reuse of single-use medical devices first began in the late 1970s. According to the Centers for Disease Control and Prevention (CDC), around 20 to 30% of the U.S. hospitals reported having reused at least one type of single-use device. The reuse of single-use devices involves ethical, regulatory, legal, medical, and economic issues, which have faced controversy in the last two decades. The reuse of single-use medical devices has increased typically due to the COVID-19 pandemic outbreak. In general, there are two categories of products that can be reused: active and inert. Active products are required for making new products, while inert products are used for making old products stronger, newer, longer-lasting, and more effective. The useful products that are generated are called inert products. These are products that have a certain amount of value because of their function. They are available in different forms like paper, paperboard, metals, plastic, etc. These products can either be reclaimed from the environment, or produced by industries and used for manufacturing purposes. The mobile devices that need to be recycled for single-use medical device reprocessing include diagnostic devices, sterilization equipment, biopsy instruments, blood glucose analyzers, blood pressure monitors, disposable gloves, medical imaging devices, and many more. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/single-use-medical-device-reprocessing.html

Seasonal influenza is caused by viruses known as influenza A, B, C, and D. These names refer to the four types of viruses, and each has a different way of entering the human body. For example, an A virus can be transmitted through the air, while B is most often transmitted through secretions from the nose or mouth. C is the most commonly caught form of the disease but does not usually spread from person to person. Influenza A viruses are the only influenza viruses known to cause flu pandemics, i.e., global epidemics of flu disease. High prevalence of acute respiratory infections is expected to propel growth of the seasonal influenza vaccines market. For instance, the study, 'Viral and Bacterial Etiologies of Acute Respiratory Infections among Children under 5 Years in Senegal', published in the journal Microbiology Insights, in February 2018, found that adenovirus was the most prevalent (50%) among selected virus species, followed by influenza virus, rhinovirus, enterovirus, and respiratory syncytial virus. Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the seasonal influenza vaccines market. For instance, globally, as of 4:25pm CET, 2 December 2020, there have been 63,360,234 confirmed cases of COVID-19, including 1,475,825 deaths, reported to the World Health Organization. Moreover, many people are getting flu shots along with COVID testing, which is also expected to aid in growth of the market. For instance, in December 2020, Tarrant County, TX, U.S., partnered with pharmacies at Kroger and Tom Thumb to help provide free flu vaccines for uninsured residents. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/emergence-of-covid-19-to-augment-growth.html

An operating room encompasses equipment such as operating tables, operating room lights, surgical booms, and operating room integration systems and surgical imaging displays. Operating room equipment include, operating table, OR lights, anesthesia machine, anesthesia cart, a stainless steel table for sterile instrument, electronic monitor, pulse oximeter machine, automated blood pressure measuring machine, electrocautery machine, a heart-lung machine, and others. Operating tables are very important for the operations of the surgery, as well as for the patient. They are often used for blood tests or other procedures that may require a quick and easy blood draw and can be very useful in this regard. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/emergence-of-covid-19-has-led-to.html

Healthcare organizations require effective management of inpatient and outpatient departments. It is essential to efficiently manage this flow, in order to ensure smooth functioning of the organization. Patient flow management solutions are one such application that enables hospitals and healthcare organizations to effectively improve the patient flow, quality of care, resource optimization & utilization, and also reduce operational cost. In hospitals, it has become extremely crucial to avoid overcrowding in emergency departments also inefficient scheduling in surgical departments. Patient flow management solutions offer certain strategies to handle and improve patient flow. One of the first things that need to be done is to establish an emergency department fast-track process, which will be integrated with tests, triage, and treatment protocols. This will streamline patient handoffs. There should be a selective surgical schedule to help relieve strain on post-operative departments. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/patient-flow-management-solutions-are.html

Primary sclerosing cholangitis (PSC) is an uncommon chronic non-inflammatory disorder typically characterized by thickening, inflammation, and fibrosis of the bile tissues within the bile (septum) or the porcine bile duct (burgh's lobules). Both the apocrine and bile ducts are involved. The lining of the small intestine also becomes thickened. Patients generally have no symptoms. However, some symptoms may occur such as diarrhea, nausea, abdominal bloating, and vomiting. Other inflammatory diseases may co-occur with psoriasis. Primary sclerosing cholangitis is also called systemic sclerosis. It is one of the most common causes of cirrhosis of the liver in the U.S. In approximately one third of patients with PSC, no identifiable disease or infection is present. In approximately twenty-five percent of patients with this disorder, the disorder is diagnosed based on history and symptoms. In approximately ten percent of individuals with this disease, specific tests for an adequate diagnosis are not performed. Approximately two-thirds of individuals with PSC do not have a history of cancer or other systemic autoimmune diseases. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/effective-treatment-is-need-of-hour-in.html

The growing incidence of viral conjunctivitis cases is driving the growth of the viral conjunctivitis drugs market. According to National Center for Biotechnology: 2017, adenovirus is the most common cause of viral conjunctivitis and up to 70% of cases of acute conjunctivitis are viral. The number of individuals affected by viral conjunctivitis is estimated to be as high as 15 to 20 million per year in the U.S. Additionally, a rising number of research and development activities for enhancing the effectiveness of viral conjunctivitis drugs is again projected to accelerate the growth of the market. For instance, in 2019, iVIEW Therapeutics Inc., a clinical-stage ophthalmology drug development company, announced the dosing of the first patient in Phase II clinical trial. iVIEW Therapeutics Inc. is testing the safety and efficacy of the IVIEW-1201 in patients (age ≥15 years) for the treatment of acute adenoviral conjunctivitis. In 2018, Starpharma Holdings Limited, a company headquartered in Australia, received a patent for SPL7013 ophthalmic drops for viral conjunctivitis from the U.S. Patent and Trademark Office. The patent has been granted to the company due to its broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis, and other eye infections. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/08/starpharma-holdings-limited-received.html

Microfluidics is an emerging technology with growing acceptability in healthcare applications. The key driver for the microfluidics market is the ‐great (or rising) demand in point-of-care (POC) and in-vitro diagnostics. For example, according to World Health Organization (WHO), 95 million people received HIV testing in low and middle-income countries in 2010.

Lung biopsy helps in detecting the stages of cancerin patients;thus, increasing the demand for biopsies across the world as it is an important tool for diagnosis and treatment. Biopsy followed by imaging tests helps in determining whether the nodule is cancerous or non-cancerous. As per WHO, in 2018, lung cancer is responsible for the largest number of deaths approximately 1.8 million deaths across the globe because of the poor prognosis for this cancer. Lower respiratory infections remained the deadliest communicable disease, causing 3.0 million deaths worldwide in 2016.

This market experienced growth in 2017 owing to surge in the use of pathological examination tests attributed to the increase in prevalence of several infectious diseases across the globe. Furthermore, surge in geriatric population and rise in health awareness are expected to foster the market growth. However, lack of reimbursement policies and decline skilled and trained healthcare professionals is anticipated to restrain the market growth during the forecast period.